{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:22:15Z","timestamp":1788380535850,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Obstetrics and Gynecology Clinics of North America"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.ogc.2008.03.007","type":"journal-article","created":{"date-parts":[[2008,5,17]],"date-time":"2008-05-17T04:45:09Z","timestamp":1210999509000},"page":"301-315","source":"Crossref","is-referenced-by-count":47,"title":["Prevention and Treatment of Postmenopausal Osteoporosis"],"prefix":"10.1016","volume":"35","author":[{"given":"E. Michael","family":"Lewiecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ogc.2008.03.007_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"Klibanski","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ogc.2008.03.007_bib2","series-title":"America's bone health: the state of osteoporosis and low bone mass in our nation","author":"National Osteoporosis Foundation","year":"2002"},{"issue":"3","key":"10.1016\/j.ogc.2008.03.007_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"Suppl","key":"10.1016\/j.ogc.2008.03.007_bib4","doi-asserted-by":"crossref","first-page":"505S","DOI":"10.1016\/8756-3282(95)00258-4","article-title":"The worldwide problem of osteoporosis: insights afforded by epidemiology","volume":"17","author":"Riggs","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.ogc.2008.03.007_bib5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a116756","article-title":"Population-based study of survival after osteoporotic fractures","volume":"137","author":"Cooper","year":"1993","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ogc.2008.03.007_bib6","series-title":"Bone health and osteoporosis: a report of the surgeon general","author":"US Department of Health and Human Services","year":"2004"},{"key":"10.1016\/j.ogc.2008.03.007_bib7","first-page":"969","article-title":"Osteoporosis among estrogen-deficient women\u2014United States, 1988\u20131994","volume":"47","author":"Centers for Disease Control and Prevention","year":"1998","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 1","key":"10.1016\/j.ogc.2008.03.007_bib8","first-page":"S193","article-title":"Longitudinal patterns in bone mass measurement among U.S. Medicare beneficiaries","volume":"22","author":"Curtis","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.ogc.2008.03.007_bib9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1359\/JBMR.041214","article-title":"Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study","volume":"20","author":"Delmas","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"18","key":"10.1016\/j.ogc.2008.03.007_bib10","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/archinte.163.18.2165","article-title":"Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures\u2014a gap in evidence-based practice guideline implementation","volume":"163","author":"Feldstein","year":"2003","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.ogc.2008.03.007_bib11","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.ogc.2008.03.007_bib12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.smj.0000221637.90495.66","article-title":"Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting","volume":"99","author":"Downey","year":"2006","journal-title":"South Med J"},{"issue":"8","key":"10.1016\/j.ogc.2008.03.007_bib13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.ogc.2008.03.007_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","article-title":"Compliance with drug therapies for the treatment and prevention of osteoporosis","volume":"48","author":"McCombs","year":"2004","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.ogc.2008.03.007_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11914-005-0014-x","article-title":"Review of guidelines for bone mineral density testing and treatment of osteoporosis","volume":"3","author":"Lewiecki","year":"2005","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"10.1016\/j.ogc.2008.03.007_bib16","first-page":"317","article-title":"Clinical applications of bone density testing for osteoporosis","volume":"96","author":"Lewiecki","year":"2005","journal-title":"Minerva Med"},{"issue":"11","key":"10.1016\/j.ogc.2008.03.007_bib17","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1210\/jc.2006-1178","article-title":"Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry","volume":"91","author":"Lewiecki","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ogc.2008.03.007_bib18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3949\/ccjm.73.8.742","article-title":"Uses and misuses of quantitative ultrasonography in managing osteoporosis","volume":"73","author":"Lewiecki","year":"2006","journal-title":"Cleve Clin J Med"},{"issue":"1","key":"10.1016\/j.ogc.2008.03.007_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocd.2007.12.007","article-title":"Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 position development conference","volume":"11","author":"Baim","year":"2008","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.ogc.2008.03.007_bib20","series-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","author":"World Health Organisation","year":"1994"},{"issue":"Suppl","key":"10.1016\/j.ogc.2008.03.007_bib21","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1385\/JCD:5:3S:S11","article-title":"Which central dual x-ray absorptiometry skeletal sites and regions of interest should be used to determine the diagnosis of osteoporosis?","volume":"5","author":"Hamdy","year":"2002","journal-title":"J\u00a0Clin Densitom"},{"issue":"5","key":"10.1016\/j.ogc.2008.03.007_bib22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4065\/77.5.453","article-title":"Secondary causes of osteoporosis","volume":"77","author":"Fitzpatrick","year":"2002","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.ogc.2008.03.007_bib23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","article-title":"Assessment of fracture risk","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ogc.2008.03.007_bib24","series-title":"Physician's guide to prevention and treatment of osteoporosis","author":"National Osteoporosis Foundation","year":"2003"},{"issue":"1","key":"10.1016\/j.ogc.2008.03.007_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00198-004-1623-4","article-title":"Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"issue":"9","key":"10.1016\/j.ogc.2008.03.007_bib26","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1359\/jbmr.2001.16.9.1694","article-title":"Neonatal bone mass: influence of parental birthweight, maternal smoking, body composition, and activity during pregnancy","volume":"16","author":"Godfrey","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"9504","key":"10.1016\/j.ogc.2008.03.007_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(06)67922-1","article-title":"Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study","volume":"367","author":"Javaid","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ogc.2008.03.007_bib28","unstructured":"Dent CE. Keynote address: problems in metabolic bone disease. Proceedings of the International Symposium on Clinical Aspects of Metabolic Bone Disease 1973. p. 1\u20137."},{"issue":"2","key":"10.1016\/j.ogc.2008.03.007_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s001980200001","article-title":"Changes in bone mineral density with age in men and women: a longitudinal study","volume":"13","author":"Warming","year":"2002","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.ogc.2008.03.007_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s001980070091","article-title":"Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women","volume":"11","author":"Chapurlat","year":"2000","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.ogc.2008.03.007_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004526.pub2","article-title":"Calcium supplementation on bone loss in postmenopausal women","author":"Shea","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.ogc.2008.03.007_bib32","doi-asserted-by":"crossref","first-page":"1987S","DOI":"10.1093\/jn\/133.6.1987S","article-title":"Interaction of science, consumer practices and policy: calcium and bone health as a case study","volume":"133","author":"Looker","year":"2003","journal-title":"J Nutr"},{"key":"10.1016\/j.ogc.2008.03.007_bib33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2362.1996.176290.x","article-title":"Vitamin D deficiency and osteoporosis: the role of vitamin D deficiency and treatment with vitamin D and analogues in the prevention of osteoporosis-related fractures","volume":"26","author":"Lips","year":"1996","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"10.1016\/j.ogc.2008.03.007_bib34","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ajcn\/75.4.611","article-title":"Vitamin D deficiency, muscle function, and falls in elderly people","volume":"75","author":"Janssen","year":"2002","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"10.1016\/j.ogc.2008.03.007_bib35","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/ajcn\/85.6.1586","article-title":"Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial","volume":"85","author":"Lappe","year":"2007","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"10.1016\/j.ogc.2008.03.007_bib36","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/01.SMJ.0000140865.32054.DB","article-title":"Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers","volume":"98","author":"Holick","year":"2005","journal-title":"South Med J"},{"issue":"7","key":"10.1016\/j.ogc.2008.03.007_bib37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00198-005-1867-7","article-title":"Estimates of optimal vitamin D status","volume":"16","author":"Dawson-Hughes","year":"2005","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.ogc.2008.03.007_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s001980050109","article-title":"The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre- and postmenopausal women","volume":"9","author":"Wolff","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ogc.2008.03.007_bib39","unstructured":"United States, Public Health Service, Office of the Surgeon General. Physical activity and health: a report of the Surgeon General. Atlanta, GA: U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996."},{"issue":"5","key":"10.1016\/j.ogc.2008.03.007_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF02390832","article-title":"A meta-analysis of the effects of cigarette smoking on bone mineral density","volume":"68","author":"Ward","year":"2001","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.1016\/j.ogc.2008.03.007_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","article-title":"Smoking and fracture risk: a meta-analysis","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ogc.2008.03.007_bib42","article-title":"Alcohol intake as a risk factor for fracture","author":"Kanis","year":"2004","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.ogc.2008.03.007_bib43","first-page":"292","article-title":"Alcohol and other factors affecting osteoporosis risk in women","volume":"26","author":"Sampson","year":"2002","journal-title":"Alcohol Res Health"},{"issue":"9","key":"10.1016\/j.ogc.2008.03.007_bib44","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ogc.2008.03.007_bib45","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.ogc.2008.03.007_bib46","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2006.11.001","article-title":"Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass","volume":"40","author":"Recker","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.ogc.2008.03.007_bib47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women","volume":"288","author":"Writing Group for the Women's Health Initiative Investigators","year":"2002","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ogc.2008.03.007_bib48","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.ogc.2008.03.007_bib49","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.ogc.2008.03.007_bib50","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.287.20.2668","article-title":"Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women","volume":"287","author":"Lindsay","year":"2002","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ogc.2008.03.007_bib51","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.290.8.1042","article-title":"Ultralow-dose micronized 17\u03b2-estradiol and bone density and bone metabolism in older women - A randomized controlled trial","volume":"290","author":"Prestwood","year":"2003","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ogc.2008.03.007_bib52","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ogc.2008.03.007_bib53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","article-title":"Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.ogc.2008.03.007_bib54","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1185\/030079905X30752","article-title":"Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE","volume":"21","author":"Chesnut","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"18","key":"10.1016\/j.ogc.2008.03.007_bib55","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ogc.2008.03.007_bib56","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","article-title":"Studies of the oral bioavailability of alendronate","volume":"58","author":"Gertz","year":"1995","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ogc.2008.03.007_bib57","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4065\/80.7.856","article-title":"Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women","volume":"80","author":"Recker","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.ogc.2008.03.007_bib58","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2006.01059.x","article-title":"Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study","volume":"60","author":"Cooper","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ogc.2008.03.007_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","article-title":"Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily for treatment of postmenopausal osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.ogc.2008.03.007_bib60","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"10.1016\/j.ogc.2008.03.007_bib61","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.ogc.2008.03.007_bib62","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ogc.2008.03.007_bib63","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.ogc.2008.03.007_bib64","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ogc.2008.03.007_bib65","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ogc.2008.03.007_bib66","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.ogc.2008.03.007_bib67","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00198-004-1798-8","article-title":"Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials","volume":"16","author":"Knopp","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ogc.2008.03.007_bib68","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ogc.2008.03.007_bib69","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1385\/JCD:6:4:307","article-title":"Nonresponders to osteoporosis therapy","volume":"6","author":"Lewiecki","year":"2003","journal-title":"J Clin Densitom"},{"issue":"7","key":"10.1016\/j.ogc.2008.03.007_bib70","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1185\/030079905X49635","article-title":"Clinical use of serum and urine bone markers in the management of osteoporosis","volume":"21","author":"Srivastava","year":"2005","journal-title":"Curr Med Res Opin"}],"container-title":["Obstetrics and Gynecology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854508000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854508000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T09:13:47Z","timestamp":1557566027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889854508000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0889854508000247"],"URL":"https:\/\/doi.org\/10.1016\/j.ogc.2008.03.007","relation":{},"ISSN":["0889-8545"],"issn-type":[{"value":"0889-8545","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}